Literature DB >> 20171174

Regulation of CYP3A4 by pregnane X receptor: The role of nuclear receptors competing for response element binding.

Monica A Istrate1, Andreas K Nussler, Michel Eichelbaum, Oliver Burk.   

Abstract

Induction of the major drug metabolizing enzyme CYP3A4 by xenobiotics contributes to the pronounced interindividual variability of its expression and often results in clinically relevant drug-drug interactions. It is mainly mediated by PXR, which regulates CYP3A4 expression by binding to several specific elements in the 5' upstream regulatory region of the gene. Induction itself shows a marked interindividual variability, whose underlying determinants are only partly understood. In this study, we investigated the role of nuclear receptor binding to PXR response elements in CYP3A4, as a potential non-genetic mechanism contributing to interindividual variability of induction. By in vitro DNA binding experiments, we showed that several nuclear receptors bind efficiently to the proximal promoter ER6 and distal xenobiotic-responsive enhancer module DR3 motifs. TRalpha1, TRbeta1, COUP-TFI, and COUP-TFII further demonstrated dose-dependent repression of PXR-mediated CYP3A4 enhancer/promoter reporter activity in transient transfection in the presence and absence of the PXR inducer rifampin, while VDR showed this effect only in the absence of treatment. By combining functional in vitro characterization with hepatic expression analysis, we predict that TRalpha1, TRbeta1, COUP-TFI, and COUP-TFII show a strong potential for the repression of PXR-mediated activation of CYP3A4 in vivo. In summary, our results demonstrate that nuclear receptor binding to PXR response elements interferes with PXR-mediated expression and induction of CYP3A4 and thereby contributes to the interindividual variability of induction. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20171174     DOI: 10.1016/j.bbrc.2010.02.058

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

1.  Opposing regulation of cytochrome P450 expression by CAR and PXR in hypothyroid mice.

Authors:  Young Joo Park; Eun Kyung Lee; Yoon Kwang Lee; Do Joon Park; Hak Chul Jang; David D Moore
Journal:  Toxicol Appl Pharmacol       Date:  2012-04-03       Impact factor: 4.219

Review 2.  Pregnane X receptor- and CYP3A4-humanized mouse models and their applications.

Authors:  Jie Cheng; Xiaochao Ma; Frank J Gonzalez
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

3.  Association between Serum Amiodarone and N-Desethylamiodarone Concentrations and Development of Thyroid Dysfunction.

Authors:  Mikie Yamato; Kyoichi Wada; Tomohiro Hayashi; Mai Fujimoto; Kouichi Hosomi; Akira Oita; Mitsutaka Takada
Journal:  Clin Drug Investig       Date:  2018-01       Impact factor: 2.859

4.  Functional characterization of a full length pregnane X receptor, expression in vivo, and identification of PXR alleles, in zebrafish (Danio rerio).

Authors:  Afonso C D Bainy; Akira Kubota; Jared V Goldstone; Roger Lille-Langøy; Sibel I Karchner; Malin C Celander; Mark E Hahn; Anders Goksøyr; John J Stegeman
Journal:  Aquat Toxicol       Date:  2013-09-20       Impact factor: 4.964

5.  Amiodarone-induced thyroid dysfunction and a perturbed N-desethyl-amiodarone to amiodarone ratio: could a drug-induced toxicity be regulating exposure to the offending agent?

Authors:  Andrew Rowland; Angela Rowland; Michael J Sorich; Arduino A Mangoni
Journal:  Eur J Clin Pharmacol       Date:  2017-05-03       Impact factor: 2.953

6.  Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients.

Authors:  Dirk Jan A R Moes; Rogier R Press; Jan den Hartigh; Tahar van der Straaten; Johan W de Fijter; Henk-Jan Guchelaar
Journal:  Clin Pharmacokinet       Date:  2012-07-01       Impact factor: 6.447

7.  Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART.

Authors:  Megan Neary; Catherine A Chappell; Kimberly K Scarsi; Shadia Nakalema; Joshua Matovu; Sharon L Achilles; Beatrice A Chen; Marco Siccardi; Andrew Owen; Mohammed Lamorde
Journal:  J Antimicrob Chemother       Date:  2019-10-01       Impact factor: 5.790

8.  Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer: A randomized drug-drug interaction study.

Authors:  Bodine P S Belderbos; Koen G A M Hussaarts; Leonie J van Harten; Esther Oomen-de Hoop; Peter de Bruijn; Paul Hamberg; Robbert J van Alphen; Brigitte C M Haberkorn; Martijn P Lolkema; Ronald de Wit; Robert J van Soest; Ron H J Mathijssen
Journal:  Br J Clin Pharmacol       Date:  2019-03-21       Impact factor: 4.335

9.  Ligand-Free Estrogen Receptor α (ESR1) as Master Regulator for the Expression of CYP3A4 and Other Cytochrome P450 Enzymes in the Human Liver.

Authors:  Danxin Wang; Rong Lu; Grzegorz Rempala; Wolfgang Sadee
Journal:  Mol Pharmacol       Date:  2019-08-09       Impact factor: 4.436

10.  Response: Amiodarone-induced thyroid dysfunction and a perturbed N-desethyl-amiodarone to amiodarone ratio; could a drug-induced toxicity be regulating exposure to the offending agent?

Authors:  Mitsutaka Takada; Mikie Yamato; Kyoichi Wada; Mai Fujimoto; Kouichi Hosomi; Tomohiro Hayashi; Akira Oita
Journal:  Eur J Clin Pharmacol       Date:  2017-04-30       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.